{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:45:41Z","timestamp":1785923141077,"version":"3.56.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Theranostics, integrating diagnostic imaging with targeted radionuclide therapy, has become central to nuclear medicine, but its global research landscape and collaboration patterns remain incompletely mapped.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize publication dynamics, cooperative networks, and emerging topics in theranostic research from 2006 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Articles and reviews indexed in the Web of Science Core Collection were retrieved for bibliometric analysis. Excel, CiteSpace, VOSviewer, Scimago Graphica, ArcGIS, and the R package bibliometrix were used for quantitative analysis and visualization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1801 articles and reviews were included, with a compound annual growth rate of 18.7%. The USA, Germany, and China were the leading producer countries, and the USA\u2013Germany collaboration showed the strongest bilateral link strength. The Helmholtz Association, Memorial Sloan Kettering Cancer Center, and the University of California System were the most productive institutions, while Herrmann K., Wester H.J., and Werner R.A. led individual output. Keyword co-occurrence analysis identified five major themes: prostate\u2010specific membrane antigen (PSMA)\u2013targeted imaging and therapy, somatostatin receptor\u2013based peptide therapy, neuroendocrine tumors, alpha-particle therapy, and fibroblast activation protein-targeted probes. Burst detection showed that fibroblast activation protein, actinium-225, and\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617 have emerged as recent research hotspots.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Theranostic research in nuclear medicine has expanded rapidly over the past two decades, with a trans-Atlantic and Asia-Pacific collaborative pattern. Current frontiers are shifting from beta-emitters toward alpha-emitters and tumor-microenvironment-targeted probes. Greater intercontinental cooperation and continued focus on novel radionuclides and under-explored targets may support future innovation and clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002183","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:00:09Z","timestamp":1779436809000},"page":"1049-1061","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evolutionary landscape and collaborative networks of global theranostic research in nuclear medicine: a visual bibliometric analysis"],"prefix":"10.1097","volume":"47","author":[{"given":"Ying-nan","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Xuzhou Central Hospital, Xuzhou, Jiangsu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Xuzhou Central Hospital, Xuzhou, Jiangsu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neuro-Intervention, Huludao Central Hospital, Huludao, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: combining imaging and therapy.","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjug Chem"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development.","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for mid-gut neuroendocrine tumours.","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer.","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for targeting fibroblast activation protein.","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping.","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature.","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.joi.2009.03.009","article-title":"From the science of science to scientometrics: visualizing the history of science with HistCite software.","volume":"3","author":"Garfield","year":"2009","journal-title":"J. Informetr"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"16569","DOI":"10.1073\/pnas.0507655102","article-title":"An index to quantify an individual\u2019s scientific research output.","volume":"102","author":"Hirsch","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-20260805","first-page":"959","article-title":"bibliometrix: an R-tool for comprehensive science mapping analysis.","volume":"111","author":"Aria","year":"2017","journal-title":"Scientometrics"},{"key":"R11-20260805","first-page":"1784","article-title":"The EANM procedure guidelines for therapy with ^177Lu-labelled PSMA-ligands.","volume":"44","author":"Zaknun","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260805","first-page":"1614","article-title":"Health-related quality of life in patients with midgut neuroendocrine tumours treated with 177Lu-Dotatate.","volume":"19","author":"Strosberg","year":"2018","journal-title":"Lancet Oncol"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls.","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","article-title":"Theranostics: From molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy \u2013 the Bad Berka experience.","volume":"2","author":"Baum","year":"2012","journal-title":"Theranostics"},{"key":"R15-20260805","first-page":"953","article-title":"Consultation on PSMA theranostics: consensus on nomenclature and future directions.","volume":"49","author":"Eiber","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20260805","first-page":"5959","article-title":"Targeted alpha therapy in oncology: recent advances and future perspectives.","volume":"27","author":"Chen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R17-20260805","first-page":"287","article-title":"68Ga-PSMA ligand PET\/CT for imaging of prostate cancer.","volume":"22","author":"Herrmann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R18-20260805","first-page":"1360","article-title":"Optimizing PSMA-targeted radioligand therapy: from tracer design to dose fractionation.","volume":"61","author":"Wester","year":"2020","journal-title":"J Nucl Med"},{"key":"R19-20260805","first-page":"27","article-title":"Results of individualized dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTATATE: the Bad Berka experience.","volume":"3","author":"Baum","year":"2013","journal-title":"Front Oncol"},{"key":"R20-20260805","first-page":"1420","article-title":"177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer and normal or near-normal renal function.","volume":"60","author":"Hofman","year":"2019","journal-title":"J Nucl Med"},{"key":"R21-20260805","first-page":"2058","article-title":"99mTc- and 177Lu-labelled fibroblast activation protein inhibitors for tumour imaging and endoradiotherapy.","volume":"48","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20260805","first-page":"109","article-title":"PSMA PET imaging in prostatic disease: clinical impact beyond prostate cancer.","volume":"9","author":"Eiber","year":"2021","journal-title":"Clin Transl Imaging"},{"key":"R23-20260805","first-page":"1965","article-title":"Influence of dosimetry on clinical outcome of 177Lu-PSMA therapy.","volume":"44","author":"Haberkorn","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20260805","first-page":"483","article-title":"Peptide receptor radionuclide therapy: therapy of neuroendocrine tumors with somatostatin analogues labeled with 177Lu.","volume":"50","author":"Kulkarni","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R25-20260805","first-page":"174","article-title":"PSMA-targeted molecular imaging and radioligand therapy of prostate cancer.","volume":"64","author":"Pomper","year":"2023","journal-title":"J Nucl Med"},{"key":"R26-20260805","first-page":"555","article-title":"Imaging of proliferation with PET in oncology.","volume":"22","author":"Buck","year":"2008","journal-title":"Ann Nucl Med"},{"key":"R27-20260805","first-page":"844","article-title":"Neuroendocrine tumours of the pancreas and digestive tract: ESMO Clinical Practice Guidelines.","volume":"31","author":"Hicks","year":"2020","journal-title":"Ann Oncol"},{"key":"R28-20260805","first-page":"469","article-title":"68Ga-Pentixafor PET\/CT for imaging of chemokine receptor CXCR4 expression in solid cancers.","volume":"60","author":"Lapa","year":"2019","journal-title":"J Nucl Med"},{"key":"R29-20260805","first-page":"108167","article-title":"Emerging radiotracers for PET imaging of tumor microenvironment.","volume":"238","author":"Zhang","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R30-20260805","first-page":"1965","article-title":"Fibroblast activation protein-targeted radionuclide therapy: clinical translation and future directions.","volume":"13","author":"Chen","year":"2023","journal-title":"Theranostics"},{"key":"R31-20260805","first-page":"2073","article-title":"Management of treatment-related toxicities after ^177Lu-DOTATATE PRRT: a practical guide.","volume":"49","author":"van der Doelen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R32-20260805","first-page":"1075","article-title":"First-in-human experience of ^225Ac-PSMA-617 for advanced prostate cancer.","volume":"49","author":"Herrmann","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2967\/jnumed.120.261016","article-title":"Production and supply of \u03b1-particle\u2013emitting radionuclides for targeted alpha therapy.","volume":"62","author":"Sgouros","year":"2021","journal-title":"J Nucl Med"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"692436","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy.","volume":"8","author":"Pouget","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R35-20260805","first-page":"1211","article-title":"Targeted \u03b1 therapy: what we need to know about ^225Ac supply chain and production.","volume":"28","author":"Gu","year":"2023","journal-title":"Molecules"},{"key":"R36-20260805","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","article-title":"Machine learning\u2013based dosimetry prediction for ^177Lu-PSMA-I&T therapy.","volume":"49","author":"Xue","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"Peptide receptor radionuclide therapy in neuroendocrine tumours: practical guidance and emerging perspectives.","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R38-20260805","first-page":"112","article-title":"Non-prostate applications of PSMA PET imaging.","volume":"17","author":"Hicks","year":"2020","journal-title":"Nat Rev Urol"},{"key":"R39-20260805","first-page":"132","article-title":"68Ga-FAPI PET\/CT improves staging and radiotherapy planning in lung cancer.","volume":"164","author":"Kratochwil","year":"2021","journal-title":"Radiother Oncol"},{"key":"R40-20260805","first-page":"3228","article-title":"High-activity 177Lu-PSMA-617 salvage therapy after ^225Ac-PSMA-617 failure.","volume":"48","author":"Calais","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R41-20260805","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms.","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"R42-20260805","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer.","volume":"56","author":"Benesov\u00e1","year":"2015","journal-title":"J Nucl Med"},{"key":"R43-20260805","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies.","volume":"56","author":"Weineisen","year":"2015","journal-title":"J Nucl Med"},{"key":"R45-20260805","doi-asserted-by":"crossref","first-page":"e19760","DOI":"10.1097\/MD.0000000000019760","article-title":"Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis.","volume":"99","author":"He","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R46-20260805","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/pros.24325","article-title":"177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis.","volume":"82","author":"Sadaghiani","year":"2022","journal-title":"Prostate"},{"key":"R47-20260805","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer.","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R48-20260805","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients.","volume":"61","author":"Meyer","year":"2020","journal-title":"J Nucl Med"},{"key":"R49-20260805","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2967\/jnumed.121.262567","article-title":"Nuclear medicine and artificial intelligence: best practices for algorithm development.","volume":"63","author":"Bradshaw","year":"2022","journal-title":"J Nucl Med"},{"key":"R50-20260805","first-page":"1211","article-title":"Targeted \u03b1 therapy: all we need to know about 225Ac\u2019s supply chain and production.","volume":"28","author":"Gu","year":"2023","journal-title":"Molecules"},{"key":"R51-20260805","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","article-title":"Application of machine learning to pre-therapeutically estimate dosimetry in men treated with 177Lu-PSMA-I&T therapy.","volume":"49","author":"Xue","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:00:38Z","timestamp":1785920438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002183","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2025-06-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}